{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:39:14Z","timestamp":1784165954309,"version":"3.55.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41391-026-01083-x","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T11:40:46Z","timestamp":1770205246000},"page":"216-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Best of 2025 in prostate cancer and prostatic diseases"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2190-512X","authenticated-orcid":false,"given":"Cosimo","family":"De Nunzio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2890-3159","authenticated-orcid":false,"given":"Riccardo","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"1083_CR1","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/s41391-025-00964-x","volume":"28","author":"A Amiri","year":"2025","unstructured":"Amiri A, Xu W, Zhang Q, Jeong JH, Freedland SJ, Fleshner NE, et al. The association between statin use, genetic variation, and prostate cancer risk. Prostate Cancer Prostatic Dis. 2025;28:953\u20139. https:\/\/doi.org\/10.1038\/s41391-025-00964-x.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR2","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s41391-025-00999-0","volume":"28","author":"CA Garc\u00eda-Becerra","year":"2025","unstructured":"Garc\u00eda-Becerra CA, Arias-Gallardo MI, Ju\u00e1rez-Garc\u00eda JE, Soltero-Molinar V, Rivera-Rocha MI, Parra-Cama\u00f1o LF, et al. Head-to-head comparison of diagnostic test accuracy between biparametric and multiparametric MRI: an updated systematic review and bivariate meta-analysis. Prostate Cancer Prostatic Dis. 2025;28:993\u20131004. https:\/\/doi.org\/10.1038\/s41391-025-00999-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR3","doi-asserted-by":"publisher","unstructured":"Zhao Y, Zhang L, Zhang S, Li J, Shi K, Yao D, et al. Machine learning-based MRI imaging for prostate cancer diagnosis: systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2025 https:\/\/doi.org\/10.1038\/s41391-025-00997-2.","DOI":"10.1038\/s41391-025-00997-2"},{"key":"1083_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/s41391-024-00932-x","volume":"28","author":"L Klotz","year":"2025","unstructured":"Klotz L, Loblaw A, Zhang L, Mamedov A, Vesprini D. Prognostic value of MR visibility\/invisibility in men on Active Surveillance. Prostate Cancer Prostatic Dis. 2025;28:879\u201386. https:\/\/doi.org\/10.1038\/s41391-024-00932-x.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR5","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41391-025-00936-1","volume":"28","author":"G Gebrael","year":"2025","unstructured":"Gebrael G, Sayegh N, Hage Chehade C, Jo Y, Narang A, Chigarira B, et al. Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy. Prostate Cancer Prostatic Dis. 2025;28:887\u201393. https:\/\/doi.org\/10.1038\/s41391-025-00936-1.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR6","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41391-025-00950-3","volume":"28","author":"G Francolini","year":"2025","unstructured":"Francolini G, Bertini N, Di Cataldo V, Garlatti P, Aquilano M, Caini S, et al. Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first-line abiraterone treatment. A subgroup analysis from the ARTO trial (NCT03449719). Prostate Cancer Prostatic Dis. 2025;28:908\u201312. https:\/\/doi.org\/10.1038\/s41391-025-00950-3.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR7","doi-asserted-by":"publisher","unstructured":"Zheng R, Friedrich NA, Luu M, Gale R, Khodyakov D, Freedland SJ, et al. Development and validation of a natural language processing system to assess the quality of physician communication in prostate cancer consultations. Prostate Cancer Prostatic Dis. 2025 https:\/\/doi.org\/10.1038\/s41391-025-01011-5.","DOI":"10.1038\/s41391-025-01011-5"},{"key":"1083_CR8","doi-asserted-by":"publisher","unstructured":"Masterson JM, Zheng R, Luu M, Murphy A, Nyame YA, Ritch C, et al. Racial and ethnic differences in valuation of life expectancy in prostate cancer treatment decision making. Prostate Cancer Prostatic Dis. 2025 https:\/\/doi.org\/10.1038\/s41391-025-01036-w.","DOI":"10.1038\/s41391-025-01036-w"},{"key":"1083_CR9","doi-asserted-by":"publisher","unstructured":"Elmansy H, Alhelal S, Blahitko O, Kelly R, Hodhod A, Abdul Hadi R, et al. Thulium fiber laser versus holmium MOSESTM laser enucleation of the prostate for the treatment of benign prostatic hyperplasia: a randomized prospective clinical study. Prostate Cancer Prostatic Dis. 2025. https:\/\/doi.org\/10.1038\/s41391-025-00996-3.","DOI":"10.1038\/s41391-025-00996-3"},{"key":"1083_CR10","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41391-025-00971-y","volume":"28","author":"C Manfredi","year":"2025","unstructured":"Manfredi C, Spirito L, Quattrone C, Bottone F, Romano L, Balsamo R, et al. Rez\u016bm water vapor therapy vs. thulium laser enucleation for the treatment of benign prostatic hyperplasia in patients with large prostates: a multicenter prospective comparative study. Prostate Cancer Prostatic Dis. 2025;28:968\u2013977. https:\/\/doi.org\/10.1038\/s41391-025-00971-y.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.mcna.2017.03.009","volume":"101","author":"MJ Barry","year":"2017","unstructured":"Barry MJ, Simmons LH. Prevention of prostate cancer morbidity and mortality: primary prevention and early detection. Med Clin North Am. 2017;101:787\u2013806. https:\/\/doi.org\/10.1016\/j.mcna.2017.03.009.","journal-title":"Med Clin North Am"},{"key":"1083_CR12","doi-asserted-by":"publisher","unstructured":"Mjaess G, Roumegu\u00e8re T, Korpak K, Van Antwerpen P, Zouaoui Boudjeltia K. Fatty acid diet and prostate cancer: a treasure hunt or a wild goose chase? Prostate Cancer Prostatic Dis. 2025;734\u20136. https:\/\/doi.org\/10.1038\/s41391-024-00854-8.","DOI":"10.1038\/s41391-024-00854-8"},{"key":"1083_CR13","doi-asserted-by":"publisher","unstructured":"Kang DW, Field CJ, Patel D, Fairey AS, Boul\u00e9 NG, Dieli-Conwright CM, et al. Effects of high-intensity interval training on cardiometabolic biomarkers in patients with prostate cancer undergoing active surveillance: a randomized controlled trial. Prostate Cancer Prostatic Dis. 2025;28:469\u201374. https:\/\/doi.org\/10.1038\/s41391-024-00867-3.","DOI":"10.1038\/s41391-024-00867-3"},{"key":"1083_CR14","doi-asserted-by":"publisher","unstructured":"Moryousef J, Duivenvoorden W, Leong D, Pinthus JH. Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies. Prostate Cancer Prostatic Dis. 2025;632\u20138. https:\/\/doi.org\/10.1038\/s41391-024-00897-x.","DOI":"10.1038\/s41391-024-00897-x"},{"key":"1083_CR15","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1159\/000518164","volume":"106","author":"Y Li","year":"2022","unstructured":"Li Y, Cheng X, Zhu J, Luo W, Xiang H, Zhang Q, et al. Effect of statins on the risk of different stages of prostate cancer: a meta-analysis. Urol Int. 2022;106:869\u201377. https:\/\/doi.org\/10.1159\/000518164.","journal-title":"Urol Int"},{"key":"1083_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/COC.0000000000001012","volume":"46","author":"Z Cao","year":"2023","unstructured":"Cao Z, Yao J, He Y, Lou D, Huang J, Zhang Y, et al. Association between statin exposure and incidence and prognosis of prostate cancer: a meta-analysis based on observational studies. Am J Clin Oncol. 2023;46:323\u201334. https:\/\/doi.org\/10.1097\/COC.0000000000001012.","journal-title":"Am J Clin Oncol"},{"key":"1083_CR17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/07853890.2020.1800074","volume":"52","author":"N Ahangari","year":"2020","unstructured":"Ahangari N, Doosti M, Ghayour Mobarhan M, Sahebkar A, Ferns GA, Pasdar A. Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy. Ann Med. 2020;52:462\u201370. https:\/\/doi.org\/10.1080\/07853890.2020.1800074.","journal-title":"Ann Med"},{"key":"1083_CR18","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41391-021-00343-2","volume":"24","author":"HB Luiting","year":"2021","unstructured":"Luiting HB, Remmers S, Valdagni R, Boev\u00e9 ER, Staerman F, Rueb J, et al. What is the effect of MRI with targeted biopsies on the rate of patients discontinuing active surveillance? A reflection of the use of MRI in the PRIAS study. Prostate Cancer Prostatic Dis. 2021;24:1048\u201354. https:\/\/doi.org\/10.1038\/s41391-021-00343-2.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR19","doi-asserted-by":"publisher","unstructured":"Xie XR, Hou Y, Shan S, Zhi R, Wu CJ, Xia YF, et al. AI-aided diagnostic performance for prostate MRI: systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2025;1\u201310. https:\/\/doi.org\/10.1038\/s41391-025-01053-9.","DOI":"10.1038\/s41391-025-01053-9"},{"key":"1083_CR20","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/s41391-025-01035-x","volume":"28","author":"X Wang","year":"2025","unstructured":"Wang X, Yan C. Clarifying the clinical role of biparametric MRI: reflections on diagnostic equivalence and patient-level stratification. Prostate Cancer Prostatic Dis. 2025;28:1026\u20137. https:\/\/doi.org\/10.1038\/s41391-025-01035-x.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR21","doi-asserted-by":"publisher","unstructured":"Driscoll CB, Handa N, Huang MM, Murphy AB, Hu JC, Schaeffer EM. Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis. Prostate Cancer Prostatic Dis. 2025;1\u20135. https:\/\/doi.org\/10.1038\/s41391-025-01057-5.","DOI":"10.1038\/s41391-025-01057-5"},{"key":"1083_CR22","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/JAMA.2025.13722","volume":"334","author":"ABCD Ng","year":"2025","unstructured":"Ng ABCD, Asif A, Agarwal R, Panebianco V, Girometti R, Ghai S, et al. Biparametric vs multiparametric MRI for prostate cancer diagnosis: the PRIME diagnostic clinical trial. JAMA. 2025;334:1170 https:\/\/doi.org\/10.1001\/JAMA.2025.13722.","journal-title":"JAMA"},{"key":"1083_CR23","doi-asserted-by":"publisher","unstructured":"Xie XR, Hou Y, Shan S, Zhi R, Wu CJ, Xia YF, et al. AI-aided diagnostic performance for prostate MRI: systematic review and meta-analysis. Prostate Cancer and Prostatic Dis. 2025;1\u201310. https:\/\/doi.org\/10.1038\/s41391-025-01053-9.","DOI":"10.1038\/s41391-025-01053-9"},{"key":"1083_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41391-024-00898-w","volume":"28","author":"HY Hougen","year":"2024","unstructured":"Hougen HY, Reis IM, Han S, Prakash NS, Thomas J, Stoyanova R, et al. Evaluating 4Kscore\u2019s role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS score. Prostate Cancer Prostatic Dis. 2024;28:180\u20136. https:\/\/doi.org\/10.1038\/s41391-024-00898-w.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR25","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1002\/IJC.34743","volume":"154","author":"TPK Lehto","year":"2024","unstructured":"Lehto TPK, Pylv\u00e4l\u00e4inen J, Sandeman K, Kentt\u00e4mies A, Nordling S, Mills IG, et al. Histomic and transcriptomic features of MRI-visible and invisible clinically significant prostate cancers are associated with prognosis. Int J Cancer. 2024;154:926\u201339. https:\/\/doi.org\/10.1002\/IJC.34743.","journal-title":"Int J Cancer"},{"key":"1083_CR26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41391-024-00901-4","volume":"28","author":"AJ Armstrong","year":"2024","unstructured":"Armstrong AJ, Taylor A, Haffner MC, Abida W, Bryce AH, Karsh LI, et al. Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2). Prostate Cancer Prostatic Dis. 2024;28:652\u201361. https:\/\/doi.org\/10.1038\/s41391-024-00901-4.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41391-024-00887-z","volume":"28","author":"AV Serritella","year":"2024","unstructured":"Serritella AV, Taylor A, Haffner MC, Abida W, Bryce A, Karsh LI, et al. Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2). Prostate Cancer Prostatic Dis. 2024;28:601\u20139. https:\/\/doi.org\/10.1038\/s41391-024-00887-z.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR28","doi-asserted-by":"publisher","unstructured":"Kanayama M, Colomba E, Shao Y, Nielsen SM, Esplin ED, Lu C, et al. Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant. Prostate Cancer Prostatic Dis. 2025;1\u20135. https:\/\/doi.org\/10.1038\/s41391-025-00994-5.","DOI":"10.1038\/s41391-025-00994-5"},{"key":"1083_CR29","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/s41391-025-00938-z","volume":"28","author":"HV Stroomberg","year":"2025","unstructured":"Stroomberg HV, Brasso K, Blak AA, Byrjalsen A, Hansen TO, R\u00f8der A. Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1\/2 variants. Prostate Cancer Prostatic Dis. 2025;28:894\u2013901. https:\/\/doi.org\/10.1038\/s41391-025-00938-z.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR30","doi-asserted-by":"publisher","unstructured":"Albertsen PC. Screening for homologous recombination genes. Prostate Cancer Prostatic Dis. 2024;541. https:\/\/doi.org\/10.1038\/s41391-024-00919-8.","DOI":"10.1038\/s41391-024-00919-8"},{"key":"1083_CR31","doi-asserted-by":"publisher","unstructured":"Saunders J, Giri VN, Vadaparampil ST, Rivera A, S\u00e1nchez Nolasco T, Rangel Camacho M, et al. Knowledge and attitudes toward prostate cancer germline genetic testing among Hispanic males. Prostate Cancer Prostatic Dis. 2025;1\u20138. https:\/\/doi.org\/10.1038\/s41391-025-01008-0.","DOI":"10.1038\/s41391-025-01008-0"},{"key":"1083_CR32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41391-024-00916-x","volume":"28","author":"J Luo","year":"2024","unstructured":"Luo J. Overcoming barriers to prostate cancer genetic testing: who, when, and how. Prostate Cancer Prostatic Dis. 2024;28:537\u20138. https:\/\/doi.org\/10.1038\/s41391-024-00916-x.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR33","doi-asserted-by":"publisher","unstructured":"Shore ND, Pieczonka CM, Heron S, Gazi M, Cahn DJ, Belkoff LH, et al. Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients. Prostate Cancer Prostatic Dis. 2025. https:\/\/doi.org\/10.1038\/s41391-025-01013-3.","DOI":"10.1038\/s41391-025-01013-3"},{"key":"1083_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41391-024-00799-y","volume":"28","author":"O Mosalem","year":"2024","unstructured":"Mosalem O, Tan W, Bryce AH, Dronca RS, Childs DS, Pagliaro LC, et al. A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and\/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis. Prostate Cancer Prostatic Dis. 2024;28:138\u201344. https:\/\/doi.org\/10.1038\/s41391-024-00799-y.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR35","doi-asserted-by":"publisher","unstructured":"Yu EY, Suzuki H, Pieczonka CM, Gotto G, Briganti A, Luz M, et al. DARolutamide observationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis. Prostate Cancer and Prostatic Diseases 2025;1\u20134. https:\/\/doi.org\/10.1038\/s41391-025-01047-7.","DOI":"10.1038\/s41391-025-01047-7"},{"key":"1083_CR36","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.23.00985","volume":"41","author":"G Francolini","year":"2023","unstructured":"Francolini G, Allegra AG, Detti B, Di Cataldo V, Caini S, Bruni A, et al. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). J Clin Oncol. 2023;41:5561\u20138. https:\/\/doi.org\/10.1200\/JCO.23.00985.","journal-title":"J Clin Oncol"},{"key":"1083_CR37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41391-023-00705-y","volume":"27","author":"A Cocci","year":"2023","unstructured":"Cocci A, Pezzoli M, Lo Re M, Russo GI, Asmundo MG, Fode M, et al. Quality of information and appropriateness of ChatGPT outputs for urology patients. Prostate Cancer Prostatic Dis. 2023;27:103\u20138. https:\/\/doi.org\/10.1038\/s41391-023-00705-y.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR38","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41391-024-00826-y","volume":"28","author":"JS Hershenhouse","year":"2024","unstructured":"Hershenhouse JS, Mokhtar D, Eppler MB, Rodler S, Storino Ramacciotti L, Ganjavi C, et al. Accuracy, readability, and understandability of large language models for prostate cancer information to the public. Prostate Cancer Prostatic Dis. 2024;28:394\u20139. https:\/\/doi.org\/10.1038\/s41391-024-00826-y.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41391-024-00789-0","volume":"28","author":"R Lombardo","year":"2024","unstructured":"Lombardo R, Gallo G, Stira J, Turchi B, Santoro G, Riolo S, et al. Quality of information and appropriateness of OpenAI outputs for prostate cancer. Prostate Cancer Prostatic Dis. 2024;28:229\u201331. https:\/\/doi.org\/10.1038\/s41391-024-00789-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR40","doi-asserted-by":"publisher","unstructured":"Rinderknecht E, Engelmann SU, Saberi V, Kirschner C, Kravchuk AP, Schmelzer A, et al. Using ChatGPT-4 for lay summarization in prostate cancer research to advance patient-centered communication: large-scale generative AI performance evaluation. J Med Internet Res. 2025;27:e76598. https:\/\/doi.org\/10.2196\/76598.","DOI":"10.2196\/76598"},{"key":"1083_CR41","doi-asserted-by":"publisher","unstructured":"Friedrich NA, Janes JL, Parrish J, De Hoedt AM, Pruett J, Fallick M, et al. Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer. Prostate Cancer Prostatic Dis. 2025;1\u20138. https:\/\/doi.org\/10.1038\/s41391-025-00995-4.","DOI":"10.1038\/s41391-025-00995-4"},{"key":"1083_CR42","doi-asserted-by":"publisher","unstructured":"Chen S, Fang Y, Cheng B. From association to action: strengthening research on social determinants of health. Prostate Cancer Prostatic Dis. 2025;1015. https:\/\/doi.org\/10.1038\/s41391-025-00967-8.","DOI":"10.1038\/s41391-025-00967-8"},{"key":"1083_CR43","doi-asserted-by":"publisher","unstructured":"Damera S, Lee JR, Hong YR, Nyame YA, Hammarlund N Negative perceptions of the health system and racial inequities in PSA screening. Prostate Cancer Prostatic Dis. 2025;1\u20137. https:\/\/doi.org\/10.1038\/s41391-025-01044-w.","DOI":"10.1038\/s41391-025-01044-w"},{"key":"1083_CR44","doi-asserted-by":"publisher","unstructured":"Alberti A, Conte F, Costagli S, Cadenar A, Nicoletti R, Pecoraro A, et al. Endoscopic enucleation vs. robot-assisted simple prostatectomy for large prostates: a systematic review and meta-analysis of patients\u2019 perspectives. Prostate Cancer Prostatic Dis. 2025;1\u201310. https:\/\/doi.org\/10.1038\/s41391-025-00973-w.","DOI":"10.1038\/s41391-025-00973-w"},{"key":"1083_CR45","doi-asserted-by":"publisher","unstructured":"Fong KY, Gauhar V, Herrmann TRW, Nedbal C, Enikeev D, Teoh JYC, et al. Machine learning models to predict postoperative incontinence after endoscopic enucleation of the prostate for benign prostatic hyperplasia: an EAU-Endourology study. Prostate Cancer Prostatic Dis. 2025;1\u20136. https:\/\/doi.org\/10.1038\/s41391-025-01015-1.","DOI":"10.1038\/s41391-025-01015-1"},{"key":"1083_CR46","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41391-025-00970-z","volume":"28","author":"LT Vo","year":"2025","unstructured":"Vo LT, Armany D, Chalasani V, Bariol SV, Baskaranathan S, Hossack T, et al. Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2025;28:845\u201358. https:\/\/doi.org\/10.1038\/s41391-025-00970-z.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR47","doi-asserted-by":"publisher","unstructured":"Pyrgidis N, Schulz GB, Weinhold P, Atzler M, Stadelmeier LF, Papadopoulos I, et al. Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study. Prostate Cancer Prostatic Dis. 2025;1\u20136. https:\/\/doi.org\/10.1038\/s41391-025-00980-x.","DOI":"10.1038\/s41391-025-00980-x"},{"key":"1083_CR48","doi-asserted-by":"publisher","unstructured":"Siron N, Zekraoui O, Lafontaine ML, Deyirmendjian C, Murad L, Pintilei T, et al. Endoscopic simulators in benign prostatic hyperplasia surgical training: a scoping review. Prostate Cancer Prostatic Dis. 2025;1\u201310. https:\/\/doi.org\/10.1038\/s41391-025-01022-2.","DOI":"10.1038\/s41391-025-01022-2"},{"key":"1083_CR49","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/s41391-025-00984-7","volume":"28","author":"D Elterman","year":"2025","unstructured":"Elterman D, Perscky I, Urena R, Codelia-Anjum A, Kadlec A, Chughtai B. Feasibility and safety study of the FlostentTM system (RAPID-I). Prostate Cancer Prostatic Dis. 2025;28:989\u201392. https:\/\/doi.org\/10.1038\/s41391-025-00984-7.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR50","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41391-024-00833-z","volume":"27","author":"SA Kaplan","year":"2024","unstructured":"Kaplan SA, Moss JL, Freedman SJ. Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study). Prostate Cancer Prostatic Dis. 2024;27:531\u20136. https:\/\/doi.org\/10.1038\/s41391-024-00833-z.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR51","doi-asserted-by":"publisher","unstructured":"De Nunzio C, Lombardo R, Cicione A, Franco A, Cornu JN MISTs for benign prostatic hyperplasia as first-line interventional treatment: Alea iacta est? Prostate Cancer Prostatic Dis. 2025;1\u20133. https:\/\/doi.org\/10.1038\/s41391-025-00986-5.","DOI":"10.1038\/s41391-025-00986-5"},{"key":"1083_CR52","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41391-024-00892-2","volume":"28","author":"S Secco","year":"2024","unstructured":"Secco S, Olivero A, Longoni M, Dell\u2019Oglio P, Tappero S, Dibilio E, et al. Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure. Prostate Cancer Prostatic Dis. 2024;28:832\u201333. https:\/\/doi.org\/10.1038\/s41391-024-00892-2.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1083_CR53","doi-asserted-by":"publisher","unstructured":"Kaplan SA, Elterman DS. New BPH therapy classification: what really FITs? Prostate Cancer Prostatic Dis. 2025;1\u20132. https:\/\/doi.org\/10.1038\/s41391-025-00985-6.","DOI":"10.1038\/s41391-025-00985-6"},{"key":"1083_CR54","unstructured":"Panel G, Lerner LB, Barry MJ, Anurag Das K, Gandhi MC, et al. Management oF Lower Urinary Tract Symptoms Attributed To Benign Prostatic Hyperplasia: AUA Guideline 2023 Amendment Panel Staff and Consultants. (2023)."},{"key":"1083_CR55","unstructured":"Cornu J, Gacci M, Hashim H. Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS) EAU Guidelines on. 2025."},{"key":"1083_CR56","doi-asserted-by":"publisher","unstructured":"Elmorsy YH, Elshal AM, EL-Nahas AR, EL-Assmy AM, Laymon M. A randomized controlled trial comparing en-bloc vs lobe-by-lobe HoLEP: surgical efficiency and early continence outcomes. Prostate Cancer Prostatic Dis. 2025. https:\/\/doi.org\/10.1038\/s41391-025-01040-0.","DOI":"10.1038\/s41391-025-01040-0"},{"key":"1083_CR57","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.1007\/S00432-023-04633-1","volume":"149","author":"S Sager","year":"2023","unstructured":"Sager S. Digital twins in oncology. J Cancer Res Clin Oncol. 2023;149:5475\u20137. https:\/\/doi.org\/10.1007\/S00432-023-04633-1.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1083_CR58","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/J.UCL.2021.03.003","volume":"48","author":"JR Mark","year":"2021","unstructured":"Mark JR, McDougall C, Giri VN. Genetic testing guidelines and education of health care providers involved in prostate cancer care. Urol Clin North Am. 2021;48:311\u201322. https:\/\/doi.org\/10.1016\/J.UCL.2021.03.003.","journal-title":"Urol Clin North Am"},{"key":"1083_CR59","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1007\/S00345-023-04524-7","volume":"41","author":"D Castellani","year":"2023","unstructured":"Castellani D, Di Rosa M, G\u00f3mez Sancha F, Rodr\u00edguez Socarr\u00e1s M, Mahajan A, Taif Bendigeri M, et al. Holmium laser with MOSES technology (MoLEP) vs Thulium fiber laser enucleation of the prostate (ThuFLEP) in a real-world setting. Mid-term outcomes from a multicenter propensity score analysis. World J Urol. 2023;41:2915\u201323. https:\/\/doi.org\/10.1007\/S00345-023-04524-7.","journal-title":"World J Urol"},{"key":"1083_CR60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/S00345-023-04748-7","volume":"42","author":"M Kosiba","year":"2024","unstructured":"Kosiba M, Filzmayer M, Welte MN, H\u00fcgenell L, Keller AC, Traumann MI, et al. Thulium fiber laser vs. holmium laser enucleation of the prostate: results of a prospective randomized non-inferiority trial. World J Urol. 2024;42:49 https:\/\/doi.org\/10.1007\/S00345-023-04748-7.","journal-title":"World J Urol."},{"key":"1083_CR61","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.prnil.2023.12.001","volume":"12","author":"EJ Lim","year":"2024","unstructured":"Lim EJ, Castellani D, Somani BK, G\u00f6kce MI, Fong KY, Sancha FG, et al. High-power holmium laser versus thulium fiber laser for endoscopic enucleation of the prostate in patients with glands larger than 80 ml: Results from the Prostate Endoscopic EnucLeation study group. Prostate Int. 2024;12:40\u20135. https:\/\/doi.org\/10.1016\/j.prnil.2023.12.001.","journal-title":"Prostate Int"},{"key":"1083_CR62","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/J.EUF.2024.12.008","volume":"11","author":"D Elterman","year":"2025","unstructured":"Elterman D, Kaplan SA. Reimagining male lower urinary tract symptoms due to benign prostatic hyperplasia treatment: a new approach to first-line interventional therapy. Eur Urol Focus. 2025;11:508\u201310. https:\/\/doi.org\/10.1016\/J.EUF.2024.12.008.","journal-title":"Eur Urol Focus"},{"key":"1083_CR63","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.eururo.2020.12.019","volume":"79","author":"S Malde","year":"2021","unstructured":"Malde S, Umbach R, Wheeler JR, Lytvyn L. A systematic review of patients\u2019 values, preferences, and expectations for the diagnosis and treatment of male lower urinary tract symptoms. Eur Urol. 2021;79:796\u2013809.","journal-title":"Eur Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01083-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01083-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01083-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:42:01Z","timestamp":1779331321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01083-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1083"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01083-x","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CDN is Editor in Chief of the journal. RL is the Associate Editor of the journal.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}